Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR2 |
Variant | G227E |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | FGFR2 G227E lies within the Ig-like C2-type domain 2 of the Fgfr2 protein (UniProt.org). The functional effect of G227E is conflicting, as it has been reported to impair receptor processing and trafficking to the cell membrane and reduce ligand-dependent cell proliferation in one study (PMID: 19147536), similar cell proliferation and viability levels to wild-type Fgfr2 in two different cell lines in another study (PMID: 29533785), and a growth advantage relative to wild-type Fgfr2 in a competition assay but transformation activity similar to wild-type Fgfr2 in cultured cells (PMID: 34272467), and therefore, its effect on Fgfr2 protein function is unknown. |
Associated Drug Resistance | |
Category Variants Paths |
FGFR2 mutant FGFR2 G227E |
Transcript | NM_000141.5 |
gDNA | chr10:g.121538660C>T |
cDNA | c.680G>A |
Protein | p.G227E |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001144913.1 | chr10:g.121538660C>T | c.680G>A | p.G227E | RefSeq | GRCh38/hg38 |
NM_000141 | chr10:g.121538660C>T | c.680G>A | p.G227E | RefSeq | GRCh38/hg38 |
NM_001144913 | chr10:g.121538660C>T | c.680G>A | p.G227E | RefSeq | GRCh38/hg38 |
NM_001144917.2 | chr10:g.121538660C>T | c.680G>A | p.G227E | RefSeq | GRCh38/hg38 |
NM_001144917.1 | chr10:g.121538660C>T | c.680G>A | p.G227E | RefSeq | GRCh38/hg38 |
NM_001144914 | chr10:g.121538660C>T | c.680G>A | p.G227E | RefSeq | GRCh38/hg38 |
NM_001144919 | chr10:g.121518822C>T | c.680G>A | p.G227E | RefSeq | GRCh38/hg38 |
NM_001144915.1 | chr10:g.121517455_121517456delGTinsAG | c.680_681delGTinsAG | p.G227E | RefSeq | GRCh38/hg38 |
NM_023029.2 | chr10:g.121517455_121517456delGTinsAG | c.680_681delGTinsAG | p.G227E | RefSeq | GRCh38/hg38 |
NM_001144917 | chr10:g.121538660C>T | c.680G>A | p.G227E | RefSeq | GRCh38/hg38 |
NM_000141.4 | chr10:g.121538660C>T | c.680G>A | p.G227E | RefSeq | GRCh38/hg38 |
NM_001320658.1 | chr10:g.121538660C>T | c.680G>A | p.G227E | RefSeq | GRCh38/hg38 |
NM_001144914.1 | chr10:g.121538660C>T | c.680G>A | p.G227E | RefSeq | GRCh38/hg38 |
NM_022970 | chr10:g.121538660C>T | c.680G>A | p.G227E | RefSeq | GRCh38/hg38 |
NM_023029 | chr10:g.121517455_121517456delACinsCT | c.680_681delGTinsAG | p.G227E | RefSeq | GRCh38/hg38 |
NM_001320658.2 | chr10:g.121538660C>T | c.680G>A | p.G227E | RefSeq | GRCh38/hg38 |
NM_022970.4 | chr10:g.121538660C>T | c.680G>A | p.G227E | RefSeq | GRCh38/hg38 |
NM_001144915.2 | chr10:g.121517455_121517456delGTinsAG | c.680_681delGTinsAG | p.G227E | RefSeq | GRCh38/hg38 |
NM_001144919.1 | chr10:g.121518822C>T | c.680G>A | p.G227E | RefSeq | GRCh38/hg38 |
NM_001144919.2 | chr10:g.121518822C>T | c.680G>A | p.G227E | RefSeq | GRCh38/hg38 |
NM_001144914.1 | chr10:g.121538660C>T | c.680G>A | p.G227E | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121538660C>T | c.680G>A | p.G227E | RefSeq | GRCh38/hg38 |
NM_000141.5 | chr10:g.121538660C>T | c.680G>A | p.G227E | RefSeq | GRCh38/hg38 |
NM_001144915 | chr10:g.121517455_121517456delACinsCT | c.680_681delGTinsAG | p.G227E | RefSeq | GRCh38/hg38 |
NM_001320658 | chr10:g.121538660C>T | c.680G>A | p.G227E | RefSeq | GRCh38/hg38 |
NM_022970.3 | chr10:g.121538660C>T | c.680G>A | p.G227E | RefSeq | GRCh38/hg38 |
NM_023029.2 | chr10:g.121517455_121517456delGTinsAG | c.680_681delGTinsAG | p.G227E | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|